NICE work announced
Guidelines on managing osteoarthritis, drug abuse, faecal incontinence and attention deficit hyperactivity disorder are to be produced by the National
Institute for Clinical Excellence as part of their “10th wave”.
Cancer treatments form a large part of the technology appraisals in the
10th wave, which include assessments of docetaxel and atrasentan for
hormone-refractory prostate cancer, cetuximab for head and neck cancer,
pemetrexed disodium for treating mesothelioma, and oxaliplatin, irinotecan
and capecitabine as adjuvant therapy in colorectal cancer. Other technology
apprasials in the pipeline include adaluminab for rheumatoid arthritis.
[See p286–91 for an article (PDF 110K) on anti-tumour necrosis factor drugs
in rheumatoid arthritis.]
|
Hospital Pharmacist